Myasthenia Gravis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, USA) As per DelveInsight's assessment, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Myasthenia Gravis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Myasthenia Gravis Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myasthenia Gravis Therapeutics Market.

The report provides a detailed description of the Myasthenia Gravis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Myasthenia Gravis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Myasthenia Gravis Pipeline Report
• Myasthenia Gravis Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.
• Leading myasthenia gravis companies such as DAS-MG, Inc, Catalyst Pharmaceuticals, Inc., Cabaletta Bio, Janssen Research & Development, LLC, Argenx, UCB Pharma, Alexion, Immunovant Sciences GmbH, Cartesian Therapeutics, Ra Pharmaceuticals, Inc., and others are developing novel myasthenia gravis drugs that can be available in the myasthenia gravis market in the coming years.
• Some of the key therapies for myasthenia gravis treatment include DAS-001, Amifampridine Phosphate, MuSK-CAART, Nipocalimab, Efgartigimod IV, Rozanolixizumab, ALXN1720, Batoclimab, Descartes-08, Zilucoplan (RA101495), and others
• In April 2023, Global biotechnology leader CSL Behring received the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
• In September 2022, Ultomiris (ravulizumab) received approval in Europe for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Myasthenia Gravis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Myasthenia Gravis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Myasthenia Gravis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myasthenia Gravis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Myasthenia Gravis Therapeutics Domain @
https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myasthenia Gravis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Myasthenia Gravis. Currently, Argenx is leading the therapeutics market with its Myasthenia Gravis drug candidates in the most advanced stage of clinical development.

Myasthenia Gravis Companies in the Therapeutics Market Include:
Ahead Therapeutics, Alexion Pharmaceuticals, Argenx, Cabaletta Bio, Cartesian Therapeutics, Catalyst Pharmaceuticals, CSL Behring, CytoDyn, DAS Therapeutics, Harbour BioMed, Hoffmann-La Roche, Horizon Therapeutics, Momenta Pharmaceuticals, Nanjing IASO Biotherapeutics, Novartis, Ra Pharmaceuticals, Rallybio, Regeneron Pharmaceuticals, RemeGen, Sanofi, Takeda, Toleranzia, UCB Pharma, Viela Bio, and others.

Emerging and Marketed Myasthenia Gravis Therapies Covered in the Report Include:
• DAS-001: DAS Therapeutics
• Descartes-08: Cartesian Therapeutics
• Efgartigimod: Argenx
• Firdapse: Catalyst Pharmaceuticals
• Hizentra: CSL Behring
• Inebilizumab: Horizon Therapeutics
• MuSK-CAART: Cabaletta Bio
• Ravulizumab: Alexion Pharmaceuticals
• RLYB116: Rallybio
• Rozanolixizumab: UCB Biopharma
• TAK-079:Takeda
• Zilucoplan: Ra Pharmaceuticals
And Many More

Mechanism of Action of the Emerging Pipeline Therapies
• Complement C5 inhibitor
• Antibody-dependent cell cytotoxicity; T lymphocyte stimulant
• Acetylcholinesterase inhibitor
• Immunologic cytotoxicity; T lymphocyte replacement
• Chloride channel antagonists
• CCR5 receptor antagonist
• Complement factor D inhibitor
• Acetylcholine inhibitor
• Neonatal FC receptor antagonist

Get an in-depth Assessment of the Emerging Therapies and Myasthenia Gravis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Myasthenia Gravis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Request for Sample PDF to Understand More About the Myasthenia Gravis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Myasthenia Gravis Current Treatment Patterns
4. Myasthenia Gravis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myasthenia Gravis Late-Stage Products (Phase-III)
7. Myasthenia Gravis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myasthenia Gravis Discontinued Products
13. Myasthenia Gravis Product Profiles
14. Myasthenia Gravis Companies
15. Myasthenia Gravis Drugs
16. Dormant and Discontinued Products
17. Myasthenia Gravis Unmet Needs
18. Myasthenia Gravis Future Perspectives
19. Myasthenia Gravis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Wound Closure Devices Market: https://www.delveinsight.com/report-store/wound-healing-devices-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/sample-request/polypoidal-choroidal-vasculopathy-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/chronic-pain-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Sanfilippo Syndrome Market: https://www.delveinsight.com/report-store/sanfilippo-syndrome-type-a-mps-iiia-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Nipah Virus Infection Market: https://www.delveinsight.com/report-store/nipah-virus-niv-infection-market
• Adrenogenital Syndrome Market: https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.